Efficacy of Micro-excisional Skin Removal by Micro-coring Device in Treatment of Wrinkles and Laxity of Face and Neck

Exclusion Criteria

• •Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be treated
• •History of keloid formation or hypertrophic scarring
• •History of trauma or surgery to the treatment areas in the past 6 months
• •Scar present in the areas to be treated
• •Silicone or synthetic material injections in the areas to be treated
• •Injection of FDA-approved dermal fillers in the past two years
• •Injection of fat in the past year
• •History of treatment with dermabrasion, ablative laser, or radiofrequency in the past year
• •History of treatment with non-ablative laser in the past 6 months
• •History of treatment with botulinum toxin injections in the areas to be treated within the prior 6 months
• •Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment
• •Active, chronic, or recurrent infection
• •History of compromised immune system or currently being treated with immunosuppressive agents
• •History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine
• •Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment
• •Treatment with aspirin or other blood thinning agents within 14 days prior to treatment
• •History or presence of any clinically significant bleeding disorder
• •Co-morbid condition that in the Investigator's opinion could limit ability to participate in the study or to comply with follow-up requirements
• •History of drug and/or alcohol abuse
• •Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or give informed consent
• •Treatment with an investigational device or agent within 30 days before treatment or during the study period